Correlation between MTA2 overexpression and tumour progression in esophageal squamous cell carcinoma

Liu, Y.P.; Shan, Baoen; Wang, X.L.; Ma, Li

doi:10.3892/etm.2012.475

Cited by 18 publications

(14 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MTA2 has been linked to tumour invasion depth, regional lymph node metastasis, distant metastasis, and poor long-term survival rates independent of age or gender in patients with esophageal squamous cell carcinoma [29], gastric cancer [13], non-small-cell lung cancer [30], and colorectal cancer [31]. Consistent with these studies, we observed higher MTA2 expression in tumour tissues compared with normal tissues and in all the RCC cell lines.…”

Section: Discussionsupporting

confidence: 89%

MTA2 as a Potential Biomarker and Its Involvement in Metastatic Progression of Human Renal Cancer by miR-133b Targeting MMP-9

Chen

Hung

et al. 2019

Cancers

View full text Add to dashboard Cite

Metastasis-associated protein 2 (MTA2) was previously known as a requirement to maintain malignant potentials in several human cancers. However, the role of MTA2 in the progression of renal cell carcinoma (RCC) has not yet been delineated. In this study, MTA2 expression was significantly increased in RCC tissues and cell lines. Increased MTA2 expression was significantly associated with tumour grade (p = 0.002) and was an independent prognostic factor for overall survival with a high RCC tumour grade. MTA2 knockdown inhibited the migration, invasion, and in vivo metastasis of RCC cells without effects on cell proliferation. Regarding molecular mechanisms, MTA2 knockdown reduced the activity, protein level, and mRNA expression of matrix metalloproteinase-9 (MMP-9) in RCC cells. Further analyses demonstrated that patients with lower miR-133b expression had poorer survival rates than those with higher expression from The Cancer Genome Atlas database. Moreover, miR-133b modulated the 3 untranslated region (UTR) of MMP-9 promoter activities and subsequently the migratory and invasive abilities of these dysregulated expressions of MTA2 in RCC cells. The inhibition of MTA2 could contribute to human RCC metastasis by regulating the expression of miR-133b targeting MMP-9 expression.

show abstract

Section: Discussionsupporting

confidence: 89%

MTA2 as a Potential Biomarker and Its Involvement in Metastatic Progression of Human Renal Cancer by miR-133b Targeting MMP-9

Chen

Hung

et al. 2019

Cancers

View full text Add to dashboard Cite

show abstract

“…MTA2 plays an important functional role in various processes related to tumorigenesis and metastasis in some solid tumors, including nasopharyngeal carcinoma, glioma, and pancreatic ductal adenocarcinoma . Recent reports have suggested that MTA2 is overexpressed in ESCC or PDAC tissues, and this overexpression is significantly correlated with lymph node metastasis and 5‐year survival rates . In the present study, the results obtained by using a clinicopathological database and TCGA database of oral tumor tissues indicated that MTA2 was positively associated with a high tumor grade and the overall survival of patients.…”

Section: Discussionsupporting

confidence: 47%

“…Our previous study suggested that MTA2 knockdown inhibits human glioma cell proliferation, induces cell cycle arrest at the G0/G1 phase, and modulates p21 and p53 expression . Moreover, MTA2 inhibition suppresses cell viability, invasion, and tumor growth by affecting the expression of p21, p27, p53, and cyclin D1 in nasopharyngeal carcinoma and breast cancer cells . Shi et al reported a significant relationship between the expression of nuclear MTA2 and Ki‐67 and the overall survival of patients with HCC.…”

Section: Discussionmentioning

confidence: 99%

Repression of metastasis‐associated protein 2 for inhibiting metastasis of human oral cancer cells by promoting the p‐cofilin‐1/ LC3‐II expression

Tseng

Chiou

Lin

et al. 2019

J Oral Pathology Medicine

View full text Add to dashboard Cite

Background The overexpression of metastasis‐associated protein 2 (MTA2) contributes to human tumor progression and metastasis in various tumor cells. However, the role of MTA2 in human oral cancer progression remains unknown. Materials and methods MTA2 expression in human oral tumor tissues and cell lines was measured by immunohistochemistry and Western blotting. Cell proliferation and cell cycle were analyzed using MTT assay and flow cytometry. The effects of MTA2 on oral cell migration and invasion were investigated using migration and invasion assays. The expression of MTA2, p‐cofilin‐1, and MTA2‐induced LC3‐II levels were measured using Western blotting and an immunofluorescence assay. Results Based on the human oral cancer tissue array and TCGA database, we found that MTA2 was increased in oral cancer tissues than in non‐tumor oral tissues (P < .01). Moreover, MTA2 is significantly associated with tumor grade (P < .01) and the overall survival rate of patients with grade III tumor (P < .05). MTA2 expression in oral cancer cells was markedly higher than that in normal oral cells. Cell proliferation and cell cycle were not significantly changed in the cells inhibited by MTA2. MTA2 knockdown can inhibit cell migration and invasion of human oral cancer cells. Furthermore, we suggest that MTA2 inhibition enhances p‐cofilin and LC3‐II expression, and the knockdown of LC3‐II expression in cells inhibited by MTA2 had the opposite effect. Conclusion These results indicate that MTA2 may serve as a candidate prognostic biomarker and that targeting autophagy is a potential therapeutic strategy for treating human oral cancer.

show abstract

“…These authors also showed strong expression of MTA2 in the ovary, heart, and lung. The upregulation of MTA2 has been reported in many cancers, such as cervical cancer [111], hepatocellular carcinoma [114], osteosarcoma [16], lung cancer [115], thymoma [116], esophageal squamous cell carcinoma [117], pancreatic ductal adenocarcinoma [118], gastric cancer [119], breast cancer [120], and glioma [121], contributing to more aggressive malignant phenotypes of cancer. MTA2 was reported to be nuclear in most reports [11,113,122]; however, in a recent report, Liu (2) et al [115] demonstrated using immunohistochemistry and immunofluorescence technologies that MTA2 was distributed in both the nucleus and cytoplasm in normal and cancer cells.…”

Section: Mta2mentioning

confidence: 99%

Subcellular localization of MTA proteins in normal and cancer cells

Liu

Wang

Huang

et al. 2014

Cancer Metastasis Rev

View full text Add to dashboard Cite

The subcellular localization of a protein is closely linked to and indicates its function. The metastatic tumor antigen (MTA) family has been under continuous investigation since its identification two decades ago. MTA1, MTA2, and MTA3 are the main members of the MTA family. MTA1, as the representative member of this family, has been shown to be widely expressed in both embryonic and adult tissues, as well as in normal and cancerous conditions, indicating that MTA1 has functions both in physiological and pathological contexts. MTA1 is expressed at a higher level in most cancers than in their normal tissue counterparts. Even in normal cells, MTA1 levels vary a great deal from tissue to tissue. Importantly, MTA1 shows a multiple localization pattern in the cell, as do MTA2 and MTA3. Different MTA components in different subcellular compartments may exert different molecular functions in the cell. Previous studies revealed that MTA1 and MTA2 are predominately localized to the nucleus, while MTA3 is observed in both the nucleus and cytoplasm. Recent studies have reported that MTA1 is located in the nucleus, cytoplasm, and the nuclear envelope. In the nucleus, MTA1 dynamically interacts with chromatin in a MTA1-K532 methylation-dependent manner, whereas cytoplasmic MTA1 binds to the microtubule skeleton. MTA1 also shows a dynamic distribution during the cell cycle. Further investigations are needed to identify the exact subcellular localizations of MTA proteins. We review the sub-cellular localization patterns of the MTA family members and give a comprehensive overview of their respective molecular activities in multiple contexts.

show abstract

Correlation between MTA2 overexpression and tumour progression in esophageal squamous cell carcinoma

Cited by 18 publications

References 16 publications

MTA2 as a Potential Biomarker and Its Involvement in Metastatic Progression of Human Renal Cancer by miR-133b Targeting MMP-9

MTA2 as a Potential Biomarker and Its Involvement in Metastatic Progression of Human Renal Cancer by miR-133b Targeting MMP-9

Repression of metastasis‐associated protein 2 for inhibiting metastasis of human oral cancer cells by promoting the p‐cofilin‐1/ LC3‐II expression

Subcellular localization of MTA proteins in normal and cancer cells

Contact Info

Product

Resources

About